Literature DB >> 35780447

Healthcare utilization and comorbidity shortly before suicide mortality in patients with attention-deficit/hyperactivity disorder: a nested case-control study.

Wan-Chen Lee1, Chun-Hung Pan1,2, Sheng-Siang Su1, Shang-Ying Tsai3,4, Chiao-Chicy Chen3,4,5,6, Chian-Jue Kuo7,8,9.   

Abstract

BACKGROUND: Few studies have analyzed healthcare utilization before suicide among individuals with attention-deficit/hyperactivity disorder (ADHD). This study examined the pattern of healthcare utilization and comorbidities shortly before death among patients with ADHD who died by suicide and compared these data with those of living controls. This study used Taiwan's National Health Insurance Research Database to identify patients with ADHD (N = 379,440) between January 1, 2001, and December 31, 2016. Subsequently, the researchers identified 159 suicide decedents by linking each patient with the National Mortality Database. By conducting a nested case-control study with risk-set sampling from the ADHD cohort, the researchers selected 20 age- and sex-matched controls (n = 3180) for each patient who died by suicide (cases). The researchers then applied conditional logistic regression to investigate differences in healthcare utilization as well as psychiatric and physical comorbidities between case patients and controls. Case patients had higher healthcare utilization within 3 months before suicide, particularly in the psychiatry, emergency, internal medicine, neurosurgery, and plastic surgery departments. These patients also had higher risks of psychiatric comorbidities, including schizophrenia, bipolar disorder, depressive disorder, and sleep disorder, as well as physical comorbidities such as hypertension and other forms of heart disease. Among patients with ADHD, suicide decedents had increased healthcare utilization and higher risks of specific psychiatric and physical comorbidities than living controls. Thus, for suicide prevention among individuals with ADHD, suicide risk must be detected early and comorbidities should be adequately managed.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  ADHD; Healthcare utilization; Physical illness; Psychiatric comorbidity; Suicide

Year:  2022        PMID: 35780447     DOI: 10.1007/s00787-022-02038-y

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  47 in total

1.  Suicidal behaviour among persons with attention-deficit hyperactivity disorder.

Authors:  Cecilie Fitzgerald; Søren Dalsgaard; Merete Nordentoft; Annette Erlangsen
Journal:  Br J Psychiatry       Date:  2019-06-07       Impact factor: 9.319

2.  Association between suicidal spectrum behaviors and Attention-Deficit/Hyperactivity Disorder: A systematic review and meta-analysis.

Authors:  Mathilde Septier; Coline Stordeur; Junhua Zhang; Richard Delorme; Samuele Cortese
Journal:  Neurosci Biobehav Rev       Date:  2019-05-24       Impact factor: 8.989

3.  Psychiatric comorbidities of adults with early- and late-onset attention-deficit/hyperactivity disorder.

Authors:  Yu-Ju Lin; Li-Kuang Yang; Susan Shur-Fen Gau
Journal:  Aust N Z J Psychiatry       Date:  2015-10-12       Impact factor: 5.744

4.  Common etiological factors of attention-deficit/hyperactivity disorder and suicidal behavior: a population-based study in Sweden.

Authors:  Therese Ljung; Qi Chen; Paul Lichtenstein; Henrik Larsson
Journal:  JAMA Psychiatry       Date:  2014-08       Impact factor: 21.596

Review 5.  Attention-deficit/hyperactivity disorder.

Authors:  Stephen V Faraone; Philip Asherson; Tobias Banaschewski; Joseph Biederman; Jan K Buitelaar; Josep Antoni Ramos-Quiroga; Luis Augusto Rohde; Edmund J S Sonuga-Barke; Rosemary Tannock; Barbara Franke
Journal:  Nat Rev Dis Primers       Date:  2015-08-06       Impact factor: 52.329

6.  Prevalence and psychiatric comorbidity of attention-deficit/hyperactivity disorder in an adolescent Finnish population.

Authors:  Susan L Smalley; James J McGough; Irma K Moilanen; Sandra K Loo; Anja Taanila; Hanna Ebeling; Tuula Hurtig; Marika Kaakinen; Lorie A Humphrey; James T McCracken; Teppo Varilo; May H Yang; Stanley F Nelson; Leena Peltonen; Marjo-Riitta Järvelin
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2007-12       Impact factor: 8.829

7.  Association of Psychiatric Comorbidity With the Risk of Premature Death Among Children and Adults With Attention-Deficit/Hyperactivity Disorder.

Authors:  Shihua Sun; Ralf Kuja-Halkola; Stephen V Faraone; Brian M D'Onofrio; Søren Dalsgaard; Zheng Chang; Henrik Larsson
Journal:  JAMA Psychiatry       Date:  2019-11-01       Impact factor: 21.596

Review 8.  Clinical practice: Adult attention deficit-hyperactivity disorder.

Authors:  Nora D Volkow; James M Swanson
Journal:  N Engl J Med       Date:  2013-11-14       Impact factor: 91.245

9.  Attention Deficit Hyperactivity Disorder Symptoms and Low Educational Achievement: Evidence Supporting A Causal Hypothesis.

Authors:  Eveline L de Zeeuw; Catharina E M van Beijsterveldt; Erik A Ehli; Eco J C de Geus; Dorret I Boomsma
Journal:  Behav Genet       Date:  2017-02-13       Impact factor: 2.805

10.  Attention-Deficit/Hyperactivity Disorder and Mortality Risk in Taiwan.

Authors:  Vincent Chin-Hung Chen; Hsiang-Lin Chan; Shu-I Wu; Meng Lee; Mong-Liang Lu; Hsin-Yi Liang; Michael E Dewey; Robert Stewart; Charles Tzu-Chi Lee
Journal:  JAMA Netw Open       Date:  2019-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.